Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Treatment of HIV / AIDS comprises antiretroviral drugs and lifestyle management ... Abacavir in the dose of 300 MG tablet is given two times a day. Associated side effects can be abdominal ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Viraday that needs to be taken just once a day for effective treatment. The three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday ...

The rate of vertical transmission of HIV ... treatment decisions. [12] Risks and benefits must be weighed and discussed with the patient before any treatment is initiated. Since zidovudine is the ...

What to avoid with this at-home COVID-19 treatment Paxlovid is a combination antiviral medication that contains nirmatrelvir (a protease inhibitor) and ritonavir (originally used to treat HIV ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

The 21-year-old biotech company has just 130 employees, no revenue and no approved drugs. But in the past ... and arimoclomol is the first approved treatment for it. Genomics: Synthetic genomics ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

in combination with an optimized background regimen in people with multi-drug resistant HIV. HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP ...

The clinical features, etiology, and treatment of recurrent aphthous ... the use of certain medications, and HIV infection. The primary goals of therapy for RAU are relief of pain, reduction ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...